Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 85~* Histologically or cytologically confirmed advanced or metastatic solid tumors~* Patients will be received femoral venepuncture for apheresis by cell separator, which is the necessary process to perform following adoptive cell immunotherapy.~* Estimated life expectancy \> 3 months~* Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR \<1.5 (unless patient is receiving warfarin in which case PT-INR must be \<3), PTT \<1.5X ULN~* Adequate renal and hepatic function, with serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.~Exclusion Criteria:~* known conditions associated with high risk of bleeding, known history of hemorrhagic diathesis~* Platelet count \< 50 000 G/L~* Active bleeding~* Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.~* Patients with obstructive jaundice~* Patients with Spleen hyperfunction~* Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.~* Pregnant or breast-feeding women，or lack of effective contraceptive treatment for women of childbearing age.;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 10mg daily (Type: EXPERIMENTAL): orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
- Rivaroxaban 20mg daily (Type: EXPERIMENTAL): orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
- Low-molecular-weight heparin (Type: ACTIVE_COMPARATOR): subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).